Dysbiosis of Gut microbiota in patients with Large-Artery Atherosclerotic Stroke: a pilot study

Abstract

Introduction: Increasing data demonstrate an association between gut microbiome in brain diseases via the gut-brain axis. However, few studies have evaluated the association between gut microbiome and large-artery atherosclerotic ischemic stroke patients.<break><break>Method: A cross-sectional pilot study was conducted among 15 patients with large-artery atherosclerotic ischemic stroke and 15 asymptomatic persons. Large-artery atherosclerotic stroke were diagnosed using TOAST classification. The control group was selected based on age- and sex-match with the patient group. Participants provided a stool sample profiled by 16S- ribosomal gene-specific methods Next-generation sequencing. The Mann-Whitney U test was used to compare the differences in gut microbiota profile between stroke and control groups. Alpha (Shannon diversity index) and beta diversity (Bray-Curtis dissimilarity) were used to evaluate gut microbial diversity. Generalized linear mixed effects models were used to relate gut microbial genus and stroke which were adjusted for age, BMI, underlying disease (diabetes, hypertension and dyslipidemia), and alcohol use.<break><break>Result: The average age of stroke patients was 61.1+7.1 and 59.2+8.2 in the control group. Beta-diversity (Bray-Curtis dissimilarity) of the gut microbiome was statistically significant in order, family and genus level (P-value=0.017, 0.011 and 0.003, respectively) between stroke and control groups; however, there was no statistically significant difference in alpha-diversity (Shannon diversity index; P-value=0.852). The relative abundance of Class Bacteriodia increased in stroke group. Using generalized linear mix effect model, we found 6 genera was significantly associated with stroke after multivariate adjustment. Ruminococcus spp.(P-value=0.017), Streptococcus spp.(P-value=0.019), Actinomyces spp.(P-value=0.02) and Dorea spp.(P-value=0.021) showed positive association while Bifidobacterium spp.(P-value=0.04) and Faecalibacterium spp.(P-value=0.041) showed negatively association with stroke.<break><break>Conclusion: Patients with large-artery atherosclerotic stroke had a decreased microbiome beta-diversity and certain gut microbiota genera may be related to large-artery atherosclerotic stroke. Future implications of this study could include the development of targeted interventions to modulate gut microbiota in order to improve outcomes for patients with large-artery atherosclerotic stroke.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Our project was supported by Pink Diamond Project, Faculty of Medicine, Chulalongkorn university, Bangkok, Thailand (Grant number 1543/2562).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All participants provided written informed consent at the time of data collection. The study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB 029/62) and adheres to the tenets of the Declaration of Helsinki. All participants' data were fully anonymized.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

Data Availability

All data generated or analysed during this study are included in this article. Further enquiries can be directed to the corresponding author.

留言 (0)

沒有登入
gif